Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

THE_MADMAN May. 19 at 2:35 PM

$CABA trading here before June 4 is meaningless. It's a binary bet. Buy now at 3.60 vs 3.20 it won't matter. They are releasing multiple data sets and if it's a home run it will moon. Having multiple programs in phase 2 isn't a 500mc company.

0 · Reply

Fundmentalstrader May. 19 at 2:31 PM

$CABA please keep selling your only saving me money on my calls thank you retards. CATTLE

0 · Reply

Bronco6970 May. 19 at 2:12 PM

$CABA this is the dead calm before the storm. Mountain of cash well into 2027, insider purchasing just a few months ago, ELI Lilly investment (they know what’s about to happen) major data release in just 2 weeks and analysts price targets as high as $30!!TAKE a look at the chart, zoom out, looks beautiful and coiled up. Let’s go Caba!! 💪👊🏻light that fuse!

1 · Reply

The1Ski May. 19 at 2:03 PM

$CABA Big outflow. Looks like it wants to retest 3

0 · Reply

D541 May. 19 at 1:58 PM

$CABA next stop 2.80

1 · Reply

vu_jade May. 19 at 1:54 PM

$CABA when you get the big spike .. take your huge gain!

0 · Reply

ABDULMOHSEN08 May. 19 at 1:40 PM

$CABA Nothing new... every day brings a new decline

1 · Reply

THE_MADMAN May. 19 at 1:07 PM

$CABA bought more can't help myself here. Not missing out on a 2x

0 · Reply

Moonman321 May. 18 at 11:46 PM

$CABA $NVDA into MAJOR upcoming data and management is getting louder, not quieter 👀 Three major healthcare conferences back-to-back: H.C. Wainwright Jefferies Goldman Sachs Biotech companies usually don’t go on an aggressive investor-marketing run before important data unless they’re confident in what they’re seeing internally. If management thought the platform was failing, they’d be hiding, conserving cash, and staying low profile — not standing in front of Wall Street every other week. 20%+ short interest. Tiny market cap. Autoimmune CAR-T / immune reset platform. Small-cap biotech rotation heating up. This setup can get violent fast once Wall Street connects the dots 🔥

0 · Reply

ABDULMOHSEN08 May. 18 at 9:39 PM

$CABA I need to delve into the mind of the person who sold 700 shares at 3.18 even though the bid price was 3.24. I want to understand why he did that?

2 · Reply

Cabaletta Bio presents new clinical data for rese-cel

2026-05-14T12:08:57.000Z - 5 days ago

Cabaletta Bio reports Q1 EPS (39c), consensus (39c)

May 14, 2026, 7:05 AM EDT - 5 days ago

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 5 days ago

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

May 14, 2026, 7:00 AM EDT - 5 days ago

Cabaletta Bio Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 5 days ago

Cabaletta Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 5 days ago

Cabaletta Bio Slides: Corporate presentation

2026-05-04T12:54:08.000Z - 15 days ago

Cabaletta Bio financing overhang concerns should be addressed, says Cantor

May 4, 2026, 6:35 AM EDT - 15 days ago

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

2026-04-28T13:02:04.000Z - 21 days ago

Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel

2026-04-28T12:38:26.000Z - 21 days ago

Cabaletta Bio, Cellares enter 10-year commercial agreement

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Cabaletta Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 21 days ago

Cabaletta Bio Proxy statement: Proxy filing

Apr 27, 2026, 5:00 PM EDT - 21 days ago

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Apr 20, 2026, 7:00 AM EDT - 4 weeks ago

Cabaletta Bio Slides: Corporate presentation

Apr 17, 2026, 8:00 AM EDT - 4 weeks ago

Cabaletta Bio Proxy statement: Proxy filing

2026-04-14T20:36:56.000Z - 4 weeks ago

Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle

Apr 14, 2026, 4:30 PM EDT - 4 weeks ago

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

2026-03-24T10:53:15.000Z - 2 months ago

Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock

JEF MS

2026-03-23T23:20:56.000Z - 2 months ago

Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley

2026-03-23T18:00:24.000Z - 2 months ago

Cabaletta Bio price target raised to $16 from $15 at Guggenheim

2026-03-23T11:40:46.000Z - 2 months ago

Cabaletta Bio reports Q4 EPS (40c), consensus (47c)

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Cabaletta Bio Annual report: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Cabaletta Bio Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Cabaletta Bio Slides: Corporate presentation

Mar 3, 2026, 11:10 AM EST - 2 months ago

Cabaletta Bio Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 9:30 AM EST - 3 months ago

Cabaletta Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 3 months ago

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-02-04T15:50:25.000Z - 3 months ago

Cabaletta Bio participates in a conference call with William Blair

2026-01-27T13:52:45.000Z - 4 months ago

Largest borrow rate increases among liquid names

BITU IAG LI NUAI SLI SVXY UVXY

2026-01-12T13:38:11.000Z - 4 months ago

Cabaletta Bio announces 2026 strategic priorities

Jan 12, 2026, 8:00 AM EST - 4 months ago

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 4 months ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Jan 11, 2026, 7:00 AM EST - 4 months ago

Cabaletta Bio Slides: Corporate presentation

2026-01-08T12:44:43.000Z - 4 months ago

Cabaletta Bio price target lowered to $14 from $22 at Morgan Stanley

2025-12-10T23:00:19.000Z - 5 months ago

Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation

Dec 5, 2025, 7:00 AM EST - 5 months ago

Cabaletta Bio Slides: Corporate Presentation

Dec 3, 2025, 1:45 PM EST - 5 months ago

Cabaletta Bio Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:20 AM EST - 6 months ago

Cabaletta Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 17, 2025, 8:30 AM EST - 6 months ago

Cabaletta Bio Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 10:30 AM EST - 6 months ago

Cabaletta Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T12:38:12.000Z - 6 months ago

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

2025-11-10T12:37:22.000Z - 6 months ago

Cabaletta Bio sees cash runway into 2H26

Nov 10, 2025, 7:30 AM EST - 6 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 6 months ago

Cabaletta Bio Quarterly report: Q3 2025

Nov 10, 2025, 7:30 AM EST - 6 months ago

Cabaletta Bio Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

2025-10-31T12:51:01.000Z - 7 months ago

Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald

2025-10-27T11:15:31.000Z - 7 months ago

Cabaletta Bio presents data, development updates for Rese-cel

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 7 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Sep 10, 2025, 11:30 AM EDT - 8 months ago

Cabaletta Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Cabaletta Bio Registration statement: Registration Filing

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cabaletta Bio Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cabaletta Bio Earnings release: Q2 2025

Jun 11, 2025, 9:54 AM EDT - 1 year ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Slides: Investor Presentation

Jun 11, 2025, 6:15 AM EDT - 1 year ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 1 year ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 9:30 AM EDT - 1 year ago

Cabaletta Bio Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

May 13, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Annual report: Q4 2024

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Mar 3, 2025, 11:50 AM EST - 1 year ago

Cabaletta Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 1 year ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 1 year ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Feb 5, 2025, 10:30 AM EST - 1 year ago

Cabaletta Bio Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Dec 4, 2024, 7:55 AM EST - 1 year ago

Cabaletta Bio Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 6:30 AM EST - 1 year ago

Cabaletta Bio Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Transcript: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Press release: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Slides: Status Update

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Earnings release: Q3 2024

Nov 11, 2024, 10:00 AM EST - 1 year ago

Cabaletta Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

Cabaletta Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Cabaletta Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 4:50 PM EDT - 1 year ago

Cabaletta Bio Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:15 AM EDT - 1 year ago

Cabaletta Bio Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 1 year ago

Cabaletta Bio Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Transcript: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Press release: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Study Update

Jun 14, 2024, 2:00 AM EDT - 2 years ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Corporate Presentation

May 13, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 9, 2024, 8:15 PM EST - 2 years ago

Cabaletta Bio Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 8:15 PM EST - 2 years ago

Cabaletta Bio Slides: FY 2024

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Earnings release: Q3 2023

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 13, 2023, 2:15 PM EDT - 2 years ago

Cabaletta Bio Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 7, 2023, 1:50 PM EDT - 2 years ago

Cabaletta Bio Transcript: Citi 18th Annual BioPharma Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Earnings release: Q2 2023

Jul 24, 2023, 8:00 AM EDT - 3 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

THE_MADMAN May. 19 at 2:35 PM

0 · Reply

Fundmentalstrader May. 19 at 2:31 PM

$CABA please keep selling your only saving me money on my calls thank you retards. CATTLE

0 · Reply

Bronco6970 May. 19 at 2:12 PM

1 · Reply

The1Ski May. 19 at 2:03 PM

$CABA Big outflow. Looks like it wants to retest 3

0 · Reply

D541 May. 19 at 1:58 PM

$CABA next stop 2.80

1 · Reply

vu_jade May. 19 at 1:54 PM

$CABA when you get the big spike .. take your huge gain!

0 · Reply

ABDULMOHSEN08 May. 19 at 1:40 PM

$CABA Nothing new... every day brings a new decline

1 · Reply

THE_MADMAN May. 19 at 1:07 PM

$CABA bought more can't help myself here. Not missing out on a 2x

0 · Reply

Moonman321 May. 18 at 11:46 PM

0 · Reply

ABDULMOHSEN08 May. 18 at 9:39 PM

$CABA I need to delve into the mind of the person who sold 700 shares at 3.18 even though the bid price was 3.24. I want to understand why he did that?

2 · Reply

MobyDick2324 May. 18 at 8:20 PM

$CABA Nice Little recovery...lets see when this downtrend is over..

1 · Reply

WastedTrader May. 18 at 8:05 PM

$CABA anyone else in here feeling a big fat buy out like 3.5 billion 6-8 months after these results come out in june?💸💸💸

2 · Reply

ABDULMOHSEN08 May. 18 at 4:25 PM

$CABA It looks like it's headed to close the gap from 2.99 to 3.17, and it also seems like the green candles aren't ready yet.

1 · Reply

The1Ski May. 18 at 3:18 PM

$CABA oversold

0 · Reply

skepticalbee May. 18 at 3:17 PM

$CABA Absolutely fucking pathetic

0 · Reply

Hongkim77 May. 18 at 3:08 PM

$CABA added more

0 · Reply

Fundmentalstrader May. 18 at 2:35 PM

$CABA manipulation at its finest i love it im going to load up on 300-500 calls before june 4th. So lower price the better roi

1 · Reply

the_conqueefador May. 18 at 2:27 PM

$CABA 3

0 · Reply

webslinger1978 May. 18 at 2:24 PM

$CABA event schedule for the next few weeks starting tomorrow:

1 · Reply

vu_jade May. 18 at 1:13 PM

Last week was a tough week overall for biotech .. Still like these names for entry $CADL $CRBU $CCCC $CABA

0 · Reply

Achandler787 May. 18 at 2:26 AM

$CABA no chance. Eli Lily just invested in and advising a micro cap biotech that has potentially transformative data out in a few weeks. Manufacturing and funding set. It’s $8 or more June 4th in my opinion. If you see $3 buy like you stole it.

4 · Reply

the_conqueefador May. 18 at 1:05 AM

$CABA 3

0 · Reply

Market Cap	368.49M
Revenue (ttm)	0.00
Net Income (ttm)	-167.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,725,600
Avg Vol	3,114,298
Day's Range	N/A - N/A
Shares Out	111.33M
Stochastic %K	10%
Beta	3.18
Analysts	Strong Sell
Price Target	$13.12